Loading…
Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS
Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and...
Saved in:
Published in: | Molecular biology reports 2024-12, Vol.51 (1), p.894, Article 894 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363 |
container_end_page | |
container_issue | 1 |
container_start_page | 894 |
container_title | Molecular biology reports |
container_volume | 51 |
creator | Atif, Muhammad Alsrhani, Abdullah Naz, Farrah Ullah, Sajjad Abdalla, Abualgasim Elgaili Ullah, Muhammad Ikram Mazhari, Bi Bi Zainab Eltayeb, Lienda Bashier Hamad, Ismail Ejaz, Hasan |
description | Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival. |
doi_str_mv | 10.1007/s11033-024-09839-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3090637633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090637633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhD3BAlrj0YvB47DjmFm35WKlSJb6uljdxWleJs9jJov57vLsFJA6cRpp53ndG8xLyEvgb4Fy_zQAckXEhGTc1GgaPyAqURiaNrh-TFUcOTNYKzsiznO845xK0ekrO0AAopWFFbpvOxymH6Gkjms80RLoPyQ00jONSmn7vcpgidbGj861Pbnf_ji5x78MQ4g2N_id1ex8Xn2k_JTon7-bDYH39fXPJwByFzebyy3PypHdD9i8e6jn59uH91_UndnX9cbNurlgrVDWzCrnyopJOKmPqCqWGbQfb3oF0ptWoVadF66ETBe874NsWwPdSKJS8xwrPycXJd5emH-Ws2Y4ht34YXPTTki1ywyvUFWJBX_-D3k1LiuW6I6UV1uJgKE5Um6ack-_tLoXRpXsL3B5ysKccbMnBHnOwUESvHqyX7ei7P5Lfjy8AnoBcRvHGp7-7_2P7C78Tj-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090753826</pqid></control><display><type>article</type><title>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</title><source>Springer Nature</source><creator>Atif, Muhammad ; Alsrhani, Abdullah ; Naz, Farrah ; Ullah, Sajjad ; Abdalla, Abualgasim Elgaili ; Ullah, Muhammad Ikram ; Mazhari, Bi Bi Zainab ; Eltayeb, Lienda Bashier ; Hamad, Ismail ; Ejaz, Hasan</creator><creatorcontrib>Atif, Muhammad ; Alsrhani, Abdullah ; Naz, Farrah ; Ullah, Sajjad ; Abdalla, Abualgasim Elgaili ; Ullah, Muhammad Ikram ; Mazhari, Bi Bi Zainab ; Eltayeb, Lienda Bashier ; Hamad, Ismail ; Ejaz, Hasan</creatorcontrib><description>Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.</description><identifier>ISSN: 0301-4851</identifier><identifier>ISSN: 1573-4978</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-024-09839-1</identifier><identifier>PMID: 39115571</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - immunology ; Adenosine ; Adenosine - metabolism ; Adenosine receptors ; Animal Anatomy ; Animal Biochemistry ; Apyrase - immunology ; Apyrase - metabolism ; Biomedical and Life Sciences ; CD8 antigen ; CD8-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - metabolism ; Cell surface ; Cell surface receptors ; COVID-19 ; COVID-19 - immunology ; COVID-19 - virology ; COVID-19 Drug Treatment ; G protein-coupled receptors ; Histology ; HIV ; Human immunodeficiency virus ; Humans ; Hypoxia ; Immune Evasion ; Immunomodulation ; Infections ; Inflammatory diseases ; Life Sciences ; Lymphocytes T ; Morphology ; Neurological diseases ; Pathophysiology ; PD-1 protein ; Receptor, Adenosine A2A - metabolism ; Review ; SARS-CoV-2 - immunology ; SARS-CoV-2 - pathogenicity ; SARS-CoV-2 - physiology ; Signal Transduction ; Viral infections</subject><ispartof>Molecular biology reports, 2024-12, Vol.51 (1), p.894, Article 894</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39115571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atif, Muhammad</creatorcontrib><creatorcontrib>Alsrhani, Abdullah</creatorcontrib><creatorcontrib>Naz, Farrah</creatorcontrib><creatorcontrib>Ullah, Sajjad</creatorcontrib><creatorcontrib>Abdalla, Abualgasim Elgaili</creatorcontrib><creatorcontrib>Ullah, Muhammad Ikram</creatorcontrib><creatorcontrib>Mazhari, Bi Bi Zainab</creatorcontrib><creatorcontrib>Eltayeb, Lienda Bashier</creatorcontrib><creatorcontrib>Hamad, Ismail</creatorcontrib><creatorcontrib>Ejaz, Hasan</creatorcontrib><title>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><addtitle>Mol Biol Rep</addtitle><description>Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Adenosine</subject><subject>Adenosine - metabolism</subject><subject>Adenosine receptors</subject><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>Apyrase - immunology</subject><subject>Apyrase - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Cell surface</subject><subject>Cell surface receptors</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>COVID-19 Drug Treatment</subject><subject>G protein-coupled receptors</subject><subject>Histology</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Immune Evasion</subject><subject>Immunomodulation</subject><subject>Infections</subject><subject>Inflammatory diseases</subject><subject>Life Sciences</subject><subject>Lymphocytes T</subject><subject>Morphology</subject><subject>Neurological diseases</subject><subject>Pathophysiology</subject><subject>PD-1 protein</subject><subject>Receptor, Adenosine A2A - metabolism</subject><subject>Review</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 - pathogenicity</subject><subject>SARS-CoV-2 - physiology</subject><subject>Signal Transduction</subject><subject>Viral infections</subject><issn>0301-4851</issn><issn>1573-4978</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhi0EokvhD3BAlrj0YvB47DjmFm35WKlSJb6uljdxWleJs9jJov57vLsFJA6cRpp53ndG8xLyEvgb4Fy_zQAckXEhGTc1GgaPyAqURiaNrh-TFUcOTNYKzsiznO845xK0ekrO0AAopWFFbpvOxymH6Gkjms80RLoPyQ00jONSmn7vcpgidbGj861Pbnf_ji5x78MQ4g2N_id1ex8Xn2k_JTon7-bDYH39fXPJwByFzebyy3PypHdD9i8e6jn59uH91_UndnX9cbNurlgrVDWzCrnyopJOKmPqCqWGbQfb3oF0ptWoVadF66ETBe874NsWwPdSKJS8xwrPycXJd5emH-Ws2Y4ht34YXPTTki1ywyvUFWJBX_-D3k1LiuW6I6UV1uJgKE5Um6ack-_tLoXRpXsL3B5ysKccbMnBHnOwUESvHqyX7ei7P5Lfjy8AnoBcRvHGp7-7_2P7C78Tj-U</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Atif, Muhammad</creator><creator>Alsrhani, Abdullah</creator><creator>Naz, Farrah</creator><creator>Ullah, Sajjad</creator><creator>Abdalla, Abualgasim Elgaili</creator><creator>Ullah, Muhammad Ikram</creator><creator>Mazhari, Bi Bi Zainab</creator><creator>Eltayeb, Lienda Bashier</creator><creator>Hamad, Ismail</creator><creator>Ejaz, Hasan</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20241201</creationdate><title>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</title><author>Atif, Muhammad ; Alsrhani, Abdullah ; Naz, Farrah ; Ullah, Sajjad ; Abdalla, Abualgasim Elgaili ; Ullah, Muhammad Ikram ; Mazhari, Bi Bi Zainab ; Eltayeb, Lienda Bashier ; Hamad, Ismail ; Ejaz, Hasan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Adenosine</topic><topic>Adenosine - metabolism</topic><topic>Adenosine receptors</topic><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>Apyrase - immunology</topic><topic>Apyrase - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Cell surface</topic><topic>Cell surface receptors</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>COVID-19 Drug Treatment</topic><topic>G protein-coupled receptors</topic><topic>Histology</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Immune Evasion</topic><topic>Immunomodulation</topic><topic>Infections</topic><topic>Inflammatory diseases</topic><topic>Life Sciences</topic><topic>Lymphocytes T</topic><topic>Morphology</topic><topic>Neurological diseases</topic><topic>Pathophysiology</topic><topic>PD-1 protein</topic><topic>Receptor, Adenosine A2A - metabolism</topic><topic>Review</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 - pathogenicity</topic><topic>SARS-CoV-2 - physiology</topic><topic>Signal Transduction</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atif, Muhammad</creatorcontrib><creatorcontrib>Alsrhani, Abdullah</creatorcontrib><creatorcontrib>Naz, Farrah</creatorcontrib><creatorcontrib>Ullah, Sajjad</creatorcontrib><creatorcontrib>Abdalla, Abualgasim Elgaili</creatorcontrib><creatorcontrib>Ullah, Muhammad Ikram</creatorcontrib><creatorcontrib>Mazhari, Bi Bi Zainab</creatorcontrib><creatorcontrib>Eltayeb, Lienda Bashier</creatorcontrib><creatorcontrib>Hamad, Ismail</creatorcontrib><creatorcontrib>Ejaz, Hasan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atif, Muhammad</au><au>Alsrhani, Abdullah</au><au>Naz, Farrah</au><au>Ullah, Sajjad</au><au>Abdalla, Abualgasim Elgaili</au><au>Ullah, Muhammad Ikram</au><au>Mazhari, Bi Bi Zainab</au><au>Eltayeb, Lienda Bashier</au><au>Hamad, Ismail</au><au>Ejaz, Hasan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><addtitle>Mol Biol Rep</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>51</volume><issue>1</issue><spage>894</spage><pages>894-</pages><artnum>894</artnum><issn>0301-4851</issn><issn>1573-4978</issn><eissn>1573-4978</eissn><abstract>Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>39115571</pmid><doi>10.1007/s11033-024-09839-1</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0301-4851 |
ispartof | Molecular biology reports, 2024-12, Vol.51 (1), p.894, Article 894 |
issn | 0301-4851 1573-4978 1573-4978 |
language | eng |
recordid | cdi_proquest_miscellaneous_3090637633 |
source | Springer Nature |
subjects | Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - immunology Adenosine Adenosine - metabolism Adenosine receptors Animal Anatomy Animal Biochemistry Apyrase - immunology Apyrase - metabolism Biomedical and Life Sciences CD8 antigen CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Cell surface Cell surface receptors COVID-19 COVID-19 - immunology COVID-19 - virology COVID-19 Drug Treatment G protein-coupled receptors Histology HIV Human immunodeficiency virus Humans Hypoxia Immune Evasion Immunomodulation Infections Inflammatory diseases Life Sciences Lymphocytes T Morphology Neurological diseases Pathophysiology PD-1 protein Receptor, Adenosine A2A - metabolism Review SARS-CoV-2 - immunology SARS-CoV-2 - pathogenicity SARS-CoV-2 - physiology Signal Transduction Viral infections |
title | Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A23%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adenosine%20A2AR%20in%20viral%20immune%20evasion%20and%20therapy:%20unveiling%20new%20avenues%20for%20treating%20COVID-19%20and%20AIDS&rft.jtitle=Molecular%20biology%20reports&rft.au=Atif,%20Muhammad&rft.date=2024-12-01&rft.volume=51&rft.issue=1&rft.spage=894&rft.pages=894-&rft.artnum=894&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-024-09839-1&rft_dat=%3Cproquest_cross%3E3090637633%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3090753826&rft_id=info:pmid/39115571&rfr_iscdi=true |